gdc-0973 and Histiocytic-Disorders--Malignant

gdc-0973 has been researched along with Histiocytic-Disorders--Malignant* in 1 studies

Trials

1 trial(s) available for gdc-0973 and Histiocytic-Disorders--Malignant

Article	Year
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature, 2019, Volume: 567, Issue:7749 Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway Topics: Azetidines; Histiocytic Disorders, Malignant; Histiocytosis; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mutation; Piperidines; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf	2019

Article

Year

Efficacy of MEK inhibition in patients with histiocytic neoplasms.

Nature, 2019, Volume: 567, Issue:7749

Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway

Topics: Azetidines; Histiocytic Disorders, Malignant; Histiocytosis; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mutation; Piperidines; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf

2019